Type 1 Diabetes Trial, Recruiting NCT07154251 Sponsor: University Hospitals Cleveland Medical Center Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT07154251
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who identify as non-Hispanic Black
  • People who have been diagnosed with type 1 diabetes and are currently being treated with insulin
  • People who are currently using, or have used in the last 3 months, an automated insulin delivery system (a device that combines a continuous glucose monitor, an insulin pump, and an automatic dosing program)
  • People who receive their diabetes care at UH Cleveland Medical Center
  • People who have not previously worked with a community health worker for help with diabetes technology

Who may not be able to join:

  • People who have been diagnosed with type 2 diabetes or a certain inherited form of diabetes called monogenic diabetes
  • People who have completed high school
  • People where at least one parent, guardian, or family support person is not willing to take part in the trial
  • People whose parents or guardians do not speak English
  • People who have not used an automated insulin delivery system within the past 3 months
  • People who have previously worked with a community health worker for help with diabetes technology
  • People who are involved with child and family services custody arrangements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sarah A MacLeish, DO, University Hospitals Cleveland Medical Center

Phone: 216-844-3661

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospitals Cleveland Medical Center
Registry
ClinicalTrials.gov
Start date
6 November 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in capillary HbA1c; Change in number of participants who use an automated insulin delivery system with at least 80% time in automated mode over the past 30 days, as measured by download of data from the automated insulin delivery system

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov